Table 1 Demographic profile of enrolled subjects.

From: Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

 

Single ascending-dose study

Multiple ascending-dose study

Food-effect study

25 mg (n = 4)

200 mg (n = 6)

400 mg (n = 6)

800 mg (n = 6)

1200 mg (n = 6)

Placebo (n = 10)

200 mg (n = 9)

400 mg (n = 9)

600 mg (n = 9)

Placebo (n = 9)

Group A* (n = 4)

Group B* (n = 4)

Group C* (n = 4)

Age, year

27.3 (7.18)

31.3 (4.89)

29.7 (5.65)

27.2 (5.12)

31.2 (7.73)

29.2 (6.80)

28.0 (3.46)

29.2 (6.34)

29.0 (6.06)

30.3 (6.73)

26.5 (4.43)

27.8 (3.83)

29.0 (7.26)

Gender

 Male

4 (100)

6 (100)

6 (100)

5 (83.3)

6 (100)

8 (80.0)

8 (88.9)

9 (100)

9 (100)

8 (88.9)

3 (75.0)

4 (100)

4 (100)

 Female

0

0

0

1 (16.7)

0

2 (20.0)

1 (11.1)

0

0

1 (11.1)

1 (25.0)

0

0

Height, cm

171.0 (6.48)

170.6 (4.33)

168.1 (2.69)

165.2 (9.07)

167.4 (5.34)

166.7 (8.62)

168.8 (7.55)

167.0 (5.08)

165.5 (3.95)

164.9 (3.92)

163.4 (4.79)

169.5 (4.98)

166.9 (4.25)

Weight, kg

65.6 (9.79)

60.3 (5.50)

62.7 (4.18)

65.0 (11.38)

63.4 (8.52)

63.8 (9.61)

64.3 (6.42)

63.9 (6.96)

60.9 (5.55)

60.5 (5.70)

57.6 (6.21)

64.6 (7.11)

63.0 (5.42)

BMI, kg/m2

22.3 (1.73)

20.7 (1.07)

22.2 (1.16)

23.7 (2.45)

22.5 (1.77)

22.8 (1.51)

22.6 (1.89)

22.9 (1.75)

22.2 (1.61)

22.2 (2.04)

21.6 (1.36)

22.4 (1.12)

22.6 (1.71)

  1. BMI body mass index.
  2. Note: Data are expressed as mean (SD), except for gender, which is shown as n (%).
  3. *Group A, B, and C experienced three treatment periods, respectively.
  4. Group A: fasting→standard meal→high-fat meal.
  5. Group B: high-fat meal→fasting→standard meal.
  6. Group C: standard meal→high-fat meal→fasting.
Back to article page